Clinical trial results
149 filings were classified as clinical trial results in the last 90 days. The most recent was Cumberland Pharmaceuticals Inc (CPIX) on Oct 23, 2026.
Latest filings
| Filed | Issuer | Event | Classified excerpt | Source |
|---|---|---|---|---|
| CPIXCumberland Pharmaceuticals Inc | Clinical trial results | “On October 23, 2026, Cumberland Pharmaceuticals Inc. ("Cumberland") announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban in this rare disease population.” | 8-K ↗ | |
| MGNXMacroGenics, Inc. | Clinical trial results | “On October 23, 2026, MacroGenics, Inc. issued a press release announcing interim data related to its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors.” | 8-K ↗ | |
| IONSIonis Pharmaceuticals, Inc. | Clinical trial results | “Results presented at the American Society of Nephrology Kidney Week 2026 also showed that, among patients with baseline hematuria ... a greater proportion of patients achieved hematuria resolution at Week 37 with sefaxersen versus placebo.” | 8-K ↗ | |
| TNGXTango Therapeutics, Inc. | Clinical trial results | “The Company observed an ORR of 82% (18 of 22 patients, with 11 of 18 confirmed partial responses ("cPRs") and 7 unconfirmed partial responses with all unconfirmed responses confirmed after the data cutoff date). Median PFS has not yet been reached. The Company also observed an 88% 9-month PFS rate and a 100% disease control rate ("DCR").” | 8-K ↗ | |
| ORICOric Pharmaceuticals, Inc. | Clinical trial results | “Enozertinib demonstrated compelling intracranial activity, including: 70% confirmed intracranial ORR by investigator... 67% (10 of 15) intracranial ORR by BICR RANO-BM... and 40% (6 of 15) intracranial complete response rate by BICR RANO-BM.” | 8-K ↗ | |
| AARDAardvark Therapeutics, Inc. | Clinical trial results | “On October 23, 2026, Aardvark Therapeutics, Inc. (the "Company") issued a press release reporting exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective ("HERO") trial and open-label extension ("OLE") trial.” | 8-K ↗ | |
| EIKNEikon Therapeutics, Inc. | Clinical trial results | “On October 23, 2026, the Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress.” The filing reports safety, tolerability, pharmacokinetic, objective response, disease-control, and duration-of-response data from multiple Phase 1/2 clinical trial cohorts.” | 8-K ↗ | |
| BOLTBolt Biotherapeutics, Inc. | Clinical trial results | “As of October 1, 2026, BDC-4182 has been administered ... to 25 subjects across 4 dose levels ... BDC-4182 was tolerated with mostly Grade 1/2 immune-related adverse events. No dose-limiting toxicities were observed ... The disease control rate ... was 53%, with 8 of 15 evaluable patients exhibiting stable disease.” | 8-K ↗ | |
| CATXPerspective Therapeutics, Inc. | Clinical trial results | “On October 23, 2026, Perspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors.” | 8-K ↗ | |
| CLYMClimb Bio, Inc. | Clinical trial results | “CLYM116 has been generally well tolerated across all dose levels evaluated with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia. Injection site reactions occurred in 5 of 88 participants across both studies, which were all Grade 1 and resolved without intervention.” | 8-K ↗ | |
| MIRAMIRA Pharmaceuticals, Inc. | Clinical trial results | “The study demonstrated that once-daily oral MIRA-55 significantly reduced mechanical and thermal pain hypersensitivity compared with vehicle-treated animals (p < 0.001). MIRA-55 achieved pain-relieving effects comparable in magnitude to celecoxib (Celebrex®), with effects sustained throughout the study without evidence of tolerance or adverse clinical signs.” | 8-K ↗ | |
| NTHINeOnc Technologies Holdings, Inc. | Clinical trial results | “On October 16, 2026, NeOnc Technologies Holdings, Inc. issued a press release announcing early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company's Compassionate Care program.” | 8-K ↗ | |
| ROIVRoivant Sciences Ltd. Common Shares | Clinical trial results | “On October 21, 2026, Roivant Sciences Ltd. issued a press release announcing positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU) conducted by its subsidiary, Priovant Therapeutics, Inc.” | 8-K ↗ | |
| IONSIonis Pharmaceuticals, Inc. | Clinical trial results | “The approval was supported by results from the Phase 3 B-Well trials showing functional cure rates of 19% in adults with ≤3000 IU/ml HBsAg, compared to current standard of care alone, which typically achieves less than 1% functional cure rate after one year of treatment.” | 8-K ↗ | |
| QNRXQuoin Pharmaceuticals, Ltd. | Clinical trial results | “Separately, in August Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome. In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215).” | 8-K ↗ | |
| FRNMFreenome, Inc. | Clinical trial results | “In the Company's PREEMPT CRC study, which enrolled more than 48,000 participants, the test demonstrated 81% sensitivity for CRC, 90% specificity for advanced colorectal neoplasia, and a 99.9% NPV in an analysis adjusted to the 2020 U.S. Census age and sex distribution.” | 8-K ↗ | |
| RAPPRapport Therapeutics, Inc. | Clinical trial results | “The trial met its primary endpoint, with RAP-219 achieving a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale ("YMRS") total score at Week 3 (mean reduction from baseline of 15.4 points with RAP-219 versus 12.3 points with placebo (p=0.045)), and RAP-219 was well tolerated.” | 8-K ↗ | |
| RCUSArcus Biosciences, Inc. | Clinical trial results | “Casdatifan monotherapy (n=121): with 28 months of median follow up in the four pooled monotherapy cohorts, median overall survival was 35 months, median PFS was 13 months and cORR was 36%.” | 8-K ↗ | |
| AVBPArriVent BioPharma, Inc. | Clinical trial results | “On October 19, 2026, ArriVent BioPharma, Inc. issued a press release announcing the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell.” | 8-K ↗ | |
| EYPTEyePoint, Inc. | Clinical trial results | “On October 19, 2026, EyePoint, Inc. issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD).” | 8-K ↗ | |
| IRONDisc Medicine, Inc. | Clinical trial results | “Bitopertin demonstrated additional quality of life benefits vs. placebo, including improved Patient Global Impression of Change (PGIC) score (p<0.0001) and Patient Global Impression of Severity (PGIS) score (p<0.0001).” | 8-K ↗ | |
| SGPSpyGlass Pharma, Inc. | Clinical trial results | “On October 19, 2026, SpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System.” | 8-K ↗ | |
| MANEVeradermics, Incorporated | Clinical trial results | “VDPHL01 achieved superior hair growth compared with placebo (p<0.0001) on the co-primary endpoints of non-vellus Target Area Hair Count and patient reported outcome benefit at Month 6. Patients achieved an average increase in non-vellus TAHC of 28.6 hairs/cm² and 36.4 hairs/cm² in the QD and BID treatment arms, respectively, compared with a 6.6 hairs/cm² increase for placebo.” | 8-K ↗ | |
| GUTSFractyl Health, Inc. | Clinical trial results | “On October 16, 2026, the Company reported topline six-month results from its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled pivotal study evaluating the safety and efficacy of Revita in maintaining weight loss after GLP-1 based therapy discontinuation. The six-month co-primary endpoint was met, with Revita participants maintaining approximately 80% of their GLP-1-induced weight loss versus 67% for sham participants (p=0.0023).” | 8-K ↗ | |
| IRDOpus Genetics, Inc. | Clinical trial results | “On October 15, 2026, Opus Genetics, Inc. issued a press release regarding the Company's October 14, 2026 presentations at the Retina in Rio 2026 conference. The presentations covered clinical data from Cohort 1 of the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 and clinical data from the Company's ongoing Phase 1/2/3 clinical trial of OPGx-LCA5.” | 8-K ↗ |
GET /stocks/filings/8-K/vX/disclosures?tertiary_category=clinical_trial_results&filing_date.gte=2026-07-28&sort=filing_date.desc&limit=1000Each category is a separate request; rows are merged and de-duplicated by filing.
{
"status": "OK",
"results": [
{
"tickers": [
"CPIX"
],
"cik": "0001087294",
"accession_number": "0001087294-26-000070",
"filing_date": "2026-10-23",
"primary_category": "operations_and_strategy",
"secondary_category": "business_developments",
"tertiary_category": "clinical_trial_results",
"supporting_text": "On October 23, 2026, Cumberland Pharmaceuticals Inc. (\"Cumberland\") announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban in this rare disease population.",
"filing_url": "https://www.sec.gov/Archives/edgar/data/1087294/0001087294-26-000070.txt"
},
{
"tickers": [
"TNGX"
],
"cik": "0001819133",
"accession_number": "0001193125-26-429423",
"filing_date": "2026-10-23",
"primary_category": "operations_and_strategy",
"secondary_category": "business_developments",
"tertiary_category": "clinical_trial_results",
"supporting_text": "The Company observed an ORR of 82% (18 of 22 patients, with 11 of 18 confirmed partial responses (\"cPRs\") and 7 unconfirmed partial responses with all unconfirmed responses confirmed after the data cutoff date). Median PFS has not yet been reached. The Company also observed an 88% 9-month PFS rate and a 100% disease control rate (\"DCR\").",
"filing_url": "https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-429423.txt"
}
]
}
// trimmed to 2 resultsShowing the 25 most recent of 149Query this data with the API
What these filings mean
- Clinical trial results
- Clinical trial data for pharma, biotech, or medical devices including efficacy and safety findings.
How this page works
- Every 8-K disclosure from the last 90 days is classified, and those in the categories above are listed here.
- One row per filing: a filing in several categories appears once.
- Labels are assigned automatically from the filing text, so always check the linked 8-K.
Other 8-K events
- Listing deficiency & delisting notices
- CEO departures
- CFO & executive departures
- Stock splits
- Merger agreements & completions
- Share buyback programs
- Dividend declarations
- Earnings releases
- Guidance updates
- Regulatory decisions
- Bankruptcy filings
- Financial restatements
- Auditor changes
- Cybersecurity incidents
- Layoffs & restructuring
Frequently asked questions
What is an SEC Form 8-K?
An 8-K is how a public company tells investors about a major event between its quarterly reports. Companies usually have four business days to file one.
How recent is this clinical trial results list?
It covers 8-K filings from the last 90 days, classified as clinical trial results and sorted newest first. The Massive 8-K disclosures API has the full, continuously updated record.
Build with AI
Track these filings with your agent
This page is built from the Massive 8-K disclosures endpoint. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check the 8-K disclosures endpoint once a day for new filings classified as clinical trial results (query tertiary_category=clinical_trial_results) and tell me about each new one, with the company, filing date, excerpt and SEC link.
Live market data from the Massive API and MCP.Get a free API key
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.